| abstract |
PURPOSE:The titled stable pharmaceutical, obtained by incorporating a higher fatty acid with a lipid used as a membrane material, and having improved affinity for the living body, retention of chemicals in the interior thereof and sustained release property of the chemicals. CONSTITUTION:A liposome pharmaceutical obtained by incorporating >=5wt%, preferably 10-15wt% higher fatty acid with a lipid, particularly phospholipid as a membrane material in a liposome pharmaceutical for retaining chemicals. A 10-20C higher fatty acid is preferred for the higher fatty acid, and particularly an 18-20C unsaturated higher fatty acid (optimally oleic acid) having 1-4 double bonds is preferred. A hydrogenated natural lecithin such as hydrogenated soybean lecithin, egg yolk lecithin or corn lecithin is preferably used as the phospholipid. |